Background and Aims: Previous studies have shown an association between Time in Range (TIR) and risk of microvascular complications, but TIR is not used widely in diabetes care. This study aimed to assess differences in awareness and use of TIR among healthcare providers (HCPs) .
Methods: In an online survey in September 2021, 303 HCPs, each working with a minimum of 30 patients with diabetes each month, were asked a series of questions related to challenges, evaluation, and goal-setting when discussing diabetes management with patients. Respondents were classified as either Endocrinologists (Endo) , Diabetes Educators (DE) , or primary care providers (PCP) . Statistical significance was tested at the 95% confidence level (p<0.05) .
Results: DEs were more likely to be aware of (96%, n=106) and use (94%, n=106) TIR in clinical practice than Endos (92%, 88%, n=98) and PCPs (56%, 46%, n=99) . Among respondents who were aware of TIR (n=247) , Endos were more likely to use TIR when making treatment decisions (87%, n=90) than PCPs (69%, n=55) . Among those who reported using TIR in clinical practice (n=234) , PCPs were least familiar (67%, n=46) with CGM metrics compared to Endos (91%, n=88) and DEs (79%, n=100) .
Conclusions: This data highlights differences in TIR use between Endos, DEs, and PCPs, and the lower levels of TIR awareness among PCPs. This study emphasizes opportunities for increased awareness of TIR through education and training of PCPs on CGM and TIR.
J.Kenney: None. A.Briskin: None. J.Tait: Employee; dQ&A. E.Shoger: Other Relationship; Diabetes industry. R.Wood: Other Relationship; Multiple companies and patient organizations (>10) . A.L.Peters: Advisory Panel; Abbott Diabetes, AstraZeneca, Eli Lilly and Company, Novo Nordisk, Shouti, Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S, Other Relationship; Omada Health, Inc., Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Leona M. and Harry B. Helmsley Charitable Trust, Stock/Shareholder; Teladoc Health.